Coronavirus Contracts

Donate
Contracts Vendors Agencies Categories States
Coronavirus Contracts
Tracking Federal Purchases to Fight the Coronavirus
Search contract descriptions, companies and agencies.
Home › All Categories › Category ›
Biomedical Applied Research/Exploratory Development R&D
Total Committed Value of Federal Contracts
$839M
Total Contracts
67
Total Actions
188

Recent Contract Actions

Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.

Description Vendor Agency Effective Estimated completion Amount Committed
HHSN275201400003I/HHSN27500040 - PULL FOR ASTHMA ROUND 2 RNA - FISHER BIOSERVICES - CAN 8473518 FISHER BIOSERVICES, INC. National Institutes of Health September 24, 2019 March 22, 2022 $0
REPOSITORY PULL FOR THE MEASUREMENT OF BIOSPECIMENS FROM THE EAGER TRIAL 2017 - FISHER BIOSERVICES, INC -EXTEND PERIOD OF PERFORMANCE DUE TO COVID-19 EMERGENCY FISHER BIOSERVICES, INC. National Institutes of Health September 24, 2019 March 22, 2022 $0
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES BATTELLE MEMORIAL INSTITUTE National Institutes of Health September 18, 2020 September 17, 2022 $1,457,965
HHSN275201400003I/HHSN27500035 - REPOSITORY PULL FOR PEAS ANALYSIS 2018 - FISHER BIOSERVICES FISHER BIOSERVICES, INC. National Institutes of Health September 24, 2019 March 22, 2022 $0
COVID-19 RELATED WORK - CLINICAL RESEARCH PRODUCTS DEVELOPMENT CENTER (CRPMC) FISHER BIOSERVICES INC. National Institutes of Health June 16, 2020 June 15, 2027 $1,196,744
TO MANAGE AND OPERATE A CGMP-COMPLIANT CLINICAL MATERIALS SERVICES FACILITY. FISHER BIOSERVICES, INC. National Institutes of Health September 11, 2017 September 21, 2022 $303,679
NIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED A MULTICENTER PLATFORM EVALUATING PUTATIVE THERAPEUTICS FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS (SHORT TITLE, LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $14,320,095
MEDICAL IMAGING AND DATA RESOURCE CENTER (MIDRC) FOR RAPID RESPONSE TO COVID-19 PANDEMIC UNIVERSITY OF CHICAGO, THE National Institutes of Health August 04, 2020 August 03, 2021 $500,000
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) EMORY UNIVERSITY National Institutes of Health January 09, 2014 July 31, 2022 $267,698
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ST. JUDE CHILDREN'S RESEARCH HOSPITAL National Institutes of Health January 09, 2014 May 20, 2022 $2,542,277
DEVICE TESTING IN A BSL2&BSL3 LAB VETERANS MEDICAL RESEARCH FOUNDATION OF SAN DIEGO Department of the Navy August 01, 2020 September 30, 2020 $26,875
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $33,788,063
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health January 09, 2014 August 01, 2022 $738,172
TO SUPPORT ON-GOING STUDIES SPECIFICALLY MICROSCOPE TIME AND SUPPLIES REQUIRED FOR CRYOEM AND INCREASED PROTEIN PRODUCTION AND CRYSTALLOGRAPHY DEMANDS, DETERMINING STRUCTURES OF ANTIBODY-BOUND SPIKE PROTEINS, DRUG SCREENING AGAINST SARS-COV-2 TARGETS NORTHWESTERN UNIVERSITY National Institutes of Health July 27, 2017 August 31, 2022 $233,258
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES BATTELLE MEMORIAL INSTITUTE National Institutes of Health September 18, 2020 September 17, 2022 $5,636,058
TO SUPPORT ON-GOING STUDIES SPECIFICALLY MICROSCOPE TIME AND SUPPLIES REQUIRED FOR CRYOEM AND INCREASED PROTEIN PRODUCTION AND CRYSTALLOGRAPHY DEMANDS, DETERMINING STRUCTURES OF ANTIBODY-BOUND SPIKE PROTEINS, DRUG SCREENING AGAINST SARS-COV-2 TARGETS SEATTLE CHILDREN'S HOSPITAL National Institutes of Health July 27, 2017 August 31, 2022 $236,790
COORDINATION OF CLINICAL TRIALS OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION COVID-19 TRACKING 2020.500 HEALTH DECISIONS, INC. National Institutes of Health July 18, 2017 July 17, 2022 $888,039
TO APPLY STATE-OF-THE-ART HIGH THROUGHPUT TECHNOLOGIES TO EXPERIMENTALLY CHARACTERIZE THE 3-D ATOMIC STRUCTURE OF PROTEINS OR OTHER MOLECULES THAT PLAY AN IMPORTANT BIOLOGICAL ROLE IN HUMAN PATHOGENS AND INFECTIOUS DISEASES. SEATTLE CHILDREN'S HOSPITAL National Institutes of Health July 27, 2017 August 31, 2022 $4,894,054
TO APPLY STATE-OF-THE-ART HIGH THROUGHPUT TECHNOLOGIES TO EXPERIMENTALLY CHARACTERIZE THE 3-D ATOMIC STRUCTURE OF PROTEINS OR OTHER MOLECULES THAT PLAY AN IMPORTANT BIOLOGICAL ROLE IN HUMAN PATHOGENS AND INFECTIOUS DISEASES. NORTHWESTERN UNIVERSITY National Institutes of Health July 27, 2017 August 31, 2022 $5,040,113
THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health September 10, 2019 August 04, 2025 $6,408,099
COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $0
COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $50,000,000
INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $23,414,109
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health January 09, 2014 August 01, 2022 $423,750
TO FUND ACTIVITIES ASSOCIATED WITH COVID-19 AND REVISE GOVERNMENT PROPERTY - SCHEDULE II-A. SEATTLE CHILDREN'S HOSPITAL National Institutes of Health July 27, 2017 August 31, 2022 $89,115
TO DEVELOP EIDD-2801, THE 5'-ISOPROPHL ESTER PRODRUG OF THE BROADLY ACTIVE ANTIVIRAL RIBONUCLEOSIDE ANALOGUE EIDD-1931, FOR THE TREATMENT OF INFLUENZA INFECTIONS. EMORY UNIVERSITY National Institutes of Health September 09, 2019 July 31, 2020 -$5,227,387
LARGE SCALE T CELL EPITOPE DISCOVERY UNIVERSITY OF WASHINGTON National Institutes of Health September 30, 2019 September 29, 2024 $0
ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS). LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $7,568,588
TOPIC 393: INTEGRATED PHOTONIC BIOSENSOR FOR PRECISION ONCOLOGY DOSE MEASUREMENTS INTELLIGENT FIBER OPTIC SYSTEMS CORPORATION National Institutes of Health September 16, 2019 December 15, 2020 $0
IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST EMERGING INFECTIOUS DISEASES INCLUDING COVID-19 (SARS-C0V2) BATTELLE MEMORIAL INSTITUTE National Institutes of Health September 18, 2020 September 17, 2022 $0
TOPIC 393: BREATH TEST FOR BIOMARKERS OF RADIATION EXPOSURE MENSSANA RESEARCH INC National Institutes of Health September 16, 2019 July 15, 2020 $0
DEVELOPMENT OF MEMBRANE ANCHORED CYTOKINES AS NOVEL VACCINE ADJUVANTS FOR THE ELDERLY. METACLIPSE THERAPEUTICS CORPORATION National Institutes of Health August 16, 2019 August 15, 2022 $2,199,976
COVID-19; NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ST. JUDE CHILDREN'S RESEARCH HOSPITAL National Institutes of Health January 09, 2014 May 20, 2022 $1,431,612
COVID-19; NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). UNIVERSITY OF ROCHESTER National Institutes of Health January 09, 2014 May 20, 2022 $151,237
COVID-19; NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) EMORY UNIVERSITY National Institutes of Health January 09, 2014 July 31, 2022 $2,176,035
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES BATTELLE MEMORIAL INSTITUTE National Institutes of Health September 18, 2020 September 17, 2022 $695,714
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). UNIVERSITY OF ROCHESTER National Institutes of Health January 09, 2014 May 20, 2022 $1,140,049
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health January 09, 2014 August 01, 2022 $2,282,925
NIAID DIVISION OF ALLERGY, IMMUNOLOGY&TRANSPLANTATION: IMMUNE-MEDIATED DISEASES CLINICAL PRODUCTS CENTER (CPC), COVID-19 EMINENT SERVICES CORPORATION National Institutes of Health April 01, 2019 March 31, 2026 $169,228
NATIONAL HISTORY OF SARS-COV-2 INFECTION REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE Centers for Disease Control and Prevention June 01, 2020 November 30, 2022 $2,677,223
LARGE SCALE T CELL EPITOPE DISCOVERY LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY National Institutes of Health September 30, 2019 September 29, 2024 $150,336
COVID-19; NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). JOHNS HOPKINS UNIVERSITY, THE National Institutes of Health January 09, 2014 May 20, 2022 $933,548
COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST AND BROADLY PROTECTIVE IMMU UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. National Institutes of Health September 10, 2019 September 09, 2022 $0
THE PURPOSE OF THIS CONTRACT IS TO CONDUCT, DEVELOP, ACQUIRE, IMPROVE, AND IMPLEMENT ASSAYS TO EVALUATE AND CHARACTERIZE THE HUMORAL IMMUNE RESPONSES OF NONHUMAN PRIMATES (NHP) THAT HAVE BEEN IMMUNIZED WITH CANDIDATE HIV OR SIV VACCINES OR INFECTED W DUKE UNIVERSITY National Institutes of Health March 28, 2018 March 29, 2025 $996,426
ABL BASE AWARD FY20 MASTER CELL BANKS MANUFACTURING FOR PANDEMIC PREPAREDNES COVID 19 CAN 8044363 $29,859.00 ADVANCED BIOSCIENCE LABORATORIES, INC. National Institutes of Health May 11, 2020 May 14, 2028 $29,859
SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS MAYO CLINIC Office of Assistant Secretary for Preparedness and Response - HHS May 01, 2020 April 30, 2022 $22,432,000
HIV IMPAACT RELATED STUDIES - MAINTAIN LIMITED INFRASTRUCTURE ACTIVITIES DURING THE COVID-19 PANDEMIC FOR THE PERIOD 04/01/2020-09/30/2020. WESTAT, INC. National Institutes of Health November 27, 2017 November 30, 2020 $456,497
IDT BIOLOGIKA BASE AWARD FY20 MASTER CELL BANKS MANUFACTURING FOR PANDEMIC PREPAREDNESS COVID 19 CAN 844363 $20,462.00 IDT BIOLOGIKA GMBH National Institutes of Health May 08, 2020 May 14, 2028 $20,462
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER). CHROMOLOGIC LLC National Institutes of Health February 28, 2017 May 10, 2022 $1,499,993
INTERNATIONAL AIDS VACCINE INITIATIVE FY20 BASE AWARD PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS COV 2 COV CAN 8044363 TOTAL $20,264.00 INTERNATIONAL AIDS VACCINE INITATIVE INC National Institutes of Health May 08, 2020 May 14, 2028 $20,264
CHANGE PI INCLUDE DIAGNOSTIC TO INCLUDE SAR COV-2 SBIR PHASE II REMOTE DIAGNOSTIC READER NOWDIAGNOSTICS, INC. National Institutes of Health September 20, 2018 September 28, 2021 $937,500
IDT BIOLOGIKA BASE FY20 PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS COV 2 CAN 8044363 TOTAL $20,462.00 IDT BIOLOGIKA GMBH National Institutes of Health May 08, 2020 May 14, 2028 $20,462
IAVI BASE AWARD FY20 MASTER CELL BANKS MANUFACTURING FOR PANDEMIC PREPAREDNESS COVID-19 CAN 8044363 $21,065.00 INTERNATIONAL AIDS VACCINE INITATIVE INC National Institutes of Health May 08, 2020 May 14, 2028 $21,065
HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY MESO SCALE DIAGNOSTICS, LLC National Institutes of Health March 14, 2017 May 10, 2021 $1,499,726
PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS COV 2 BASE AWARD, COV CAN 8044363 TOTAL $31,202.00 ADVANCED BIOSCIENCE LABORATORIES, INC. National Institutes of Health May 11, 2020 May 14, 2028 $31,202
TO DEVELOP EIDD-2801, THE 5'-ISOPROPHL ESTER PRODRUG OF THE BROADLY ACTIVE ANTIVIRAL RIBONUCLEOSIDE ANALOGUE EIDD-1931, FOR THE TREATMENT OF INFLUENZA INFECTIONS. EMORY UNIVERSITY National Institutes of Health September 09, 2019 July 31, 2020 $0
ESTABLISH A VIRTUAL NETWORK TO INVESTIGATE THE TRAJECTORY OF COVID-19-RELATED SEVERE OUTCOMES WESTAT, INC. Centers for Disease Control and Prevention May 04, 2020 September 30, 2022 $1,743,949
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health January 09, 2014 August 01, 2022 $1,184,771
INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $10,104,139
NIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED A MULTICENTER PLATFORM EVALUATING PUTATIVE THERAPEUTICS FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS (SHORT TITLE, LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $11,490,292
SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS MAYO CLINIC Office of Assistant Secretary for Preparedness and Response - HHS May 01, 2020 April 30, 2022 $26,495,887
TO EXTEND THE PERIOD OF PERFORMANCE AT NO ADDITIONAL COST, DUE TO THE TEMPORARY STOPPAGE IN OPERATIONS AS A RESULT OF THE COVID-19 QUARANTINE. GENCIRQ, INC. National Institutes of Health July 31, 2019 October 31, 2020 $0
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ST. JUDE CHILDREN'S RESEARCH HOSPITAL National Institutes of Health January 09, 2014 May 20, 2022 $500,000
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) EMORY UNIVERSITY National Institutes of Health January 09, 2014 July 31, 2022 $1,032,857
B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION. WASHINGTON UNIVERSITY, THE National Institutes of Health September 16, 2019 March 15, 2022 $0
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES BATTELLE MEMORIAL INSTITUTE National Institutes of Health September 18, 2020 September 17, 2022 $2,254,547
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health January 09, 2014 August 01, 2022 $423,750
THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health September 10, 2019 August 04, 2025 $3,051,550
IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST EMERGING INFECTIOUS DISEASES INCLUDING COVID-19 (SARS-C0V2) BATTELLE MEMORIAL INSTITUTE National Institutes of Health September 18, 2020 September 17, 2022 $2,429,847
COVID-19. OPTION PERIOD TWO. 04/16/2020-08/31/2020. STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES. SEATTLE CHILDREN'S HOSPITAL National Institutes of Health July 27, 2017 August 31, 2022 $351,959
COVID-19. OPTION PERIOD TWO. 04-16/2020 - 08/31/2020. STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES. NORTHWESTERN UNIVERSITY National Institutes of Health July 27, 2017 August 31, 2022 $358,163
B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION INTEGRAL MOLECULAR, INC National Institutes of Health September 16, 2019 April 12, 2021 $1,000,000
TO DEVELOP EIDD-2801, THE 5'-ISOPROPHL ESTER PRODRUG OF THE BROADLY ACTIVE ANTIVIRAL RIBONUCLEOSIDE ANALOGUE EIDD-1931, FOR THE TREATMENT OF INFLUENZA INFECTIONS. EMORY UNIVERSITY National Institutes of Health September 09, 2019 July 31, 2020 $5,227,387
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). UNIVERSITY OF ROCHESTER National Institutes of Health January 09, 2014 May 20, 2022 $616,121
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). JOHNS HOPKINS UNIVERSITY, THE National Institutes of Health January 09, 2014 May 20, 2022 $1,649,167
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ST. JUDE CHILDREN'S RESEARCH HOSPITAL National Institutes of Health January 09, 2014 May 20, 2022 $905,954
RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA HDT BIO CORP. National Institutes of Health September 01, 2019 August 31, 2021 $0
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $33,571,749
INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19". LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $6,680,834
ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS). LEIDOS BIOMEDICAL RESEARCH, INC. National Institutes of Health August 31, 2020 August 30, 2024 $4,926,752
LARGE SCALE T CELL EPITOPE DISCOVERY LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY National Institutes of Health September 30, 2019 September 29, 2024 $500,000
BPCA PHARMACOLOGY STUDIES - PERIOD OF PERFORMANCE: 9/14/18 - 9/13/22 DUKE UNIVERSITY National Institutes of Health September 11, 2018 September 13, 2022 $1,745,388
B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION VANDERBILT UNIVERSITY MEDICAL CENTER National Institutes of Health September 16, 2019 September 15, 2024 $1,536,727
B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION. WASHINGTON UNIVERSITY, THE National Institutes of Health September 16, 2019 March 15, 2022 -$0
B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION. WASHINGTON UNIVERSITY, THE National Institutes of Health September 16, 2019 March 15, 2022 $1,810,144
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ST. JUDE CHILDREN'S RESEARCH HOSPITAL National Institutes of Health January 09, 2014 May 20, 2022 $14,335,211
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI National Institutes of Health January 09, 2014 August 01, 2022 $7,948,790
B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION. WASHINGTON UNIVERSITY, THE National Institutes of Health September 16, 2019 March 15, 2022 $1,810,144
2 Next ›
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.
Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page